IP Library Granted Patent US 7,763,743
Granted Patent B2
US 7,763,743 · App. 11/592,448 · Granted Jul 27, 2010

Intermediates for the preparation of lipoxin A

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,763,743
App. No.
11/592,448
Granted
Jul 27, 2010
Kind
B2
Abstract

This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A 4 analogs of the following formulas (I) and (II): wherein R 1 , R 2 , R 3 , R 4 and R 5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.

Claims (59)

1. A compound of the following formula:

wherein,

R 7a is hydrogen, alkyl, aryl, or aralkyl;

R 10 is a straight or branched alkylene chain, a straight or branched alkenylene chain, a straight or branched alkynylene chain, or cycloalkylene; and

each of R 14 and R 14a is independently hydrogen or alkyl;

as a single stereoisomer, a mixture of stereoisomers, or a racemic mixture of stereoisomers.

2. The compound according to claim 1 wherein R 14 is methyl and R 14a is hydrogen.

3. The compound according to claim 2 wherein R 10 is methylene and R 7a is alkyl.

4. The compound according to claim 3 wherein R 7a is methyl or tert-butyl.

5. A compound of the following formula:

wherein,

R 7a is hydrogen, alkyl, aryl, or aralkyl;

R 10 is a straight or branched alkylene chain, a straight or branched alkenylene chain, a straight or branched alkynylene chain, or cycloalkylene; and

each of R 14 and R 14a is independently hydrogen or alkyl;

as a single stereoisomer, a mixture of stereoisomers, or a racemic mixture of stereoisomers.

6. The compound according to claim 5 wherein R 14 is methyl and R 14a is hydrogen.

7. The compound according to claim 6 wherein R 10 is methylene and R 7a is alkyl.

8. The compound according to claim 7 wherein R 7a is methyl or tert-butyl.

9. A compound of the following formula (1) or (2):

wherein,

XX is hydrogen or a suitable protecting group;

R 7a is hydrogen, alkyl, aryl, or aralkyl;

R 10 is a straight or branched alkylene chain, a straight or branched alkenylene chain, a straight or branched alkynylene chain, or cycloalkylene; and

each of R 14 and R 14a is independently hydrogen or alkyl;

as a single stereoisomer, a mixture of stereoisomers, or a racemic mixture of stereoisomers.

10. The compound according to claim 9 wherein R 14 is methyl and R 14a is hydrogen.

11. The compound according to claim 10 wherein R 10 is methylene and R 7a is alkyl.

12. The compound according to claim 11 wherein R 7a is methyl or tert-butyl.

13. A compound having the following formula:

wherein,

R 3 is halo, —OR 6 , —SR 6 , —S(O) t R 7 (where t is 1 or 2) or —N(R 7 )R 8 ;

R 5 is aryl (optionally substituted by one or more substituents selected from alkyl, alkoxy, halo, haloalkyl and haloalkoxy) or aralkyl (optionally substituted by one or more substituents selected from alkyl, alkoxy, halo, haloalkyl and haloalkoxy);

each R 6 is independently hydrogen, alkyl, aryl, aralkyl, —C(O)R 7 , —C(S)R 7 , —C(O)OR 14 ,

—C(S)OR 14 ,

—C(O)N(R 7 )R 8 , or —C(S)N(R 7 )R 8 ;

each R 7 is independently hydrogen, alkyl, cycloalkyl, aryl, or aralkyl;

R 7a is hydrogen, alkyl, aryl, or aralkyl;

each R 8 is independently hydrogen, alkyl, aryl, aralkyl, —C(O)R 7 , —C(O)OR 14 , or cycloalkyl (optionally substituted with one more substituents selected from alkyl, —N(R 7 ) 2 , and —C(O)OR 7 );

R 10 is a straight or branched alkylene chain, a straight or branched alkenylene chain, a straight or branched alkynylene chain, or cycloalkylene; and

each of R 14 and R 14a is independently hydrogen or alkyl;

as a single stereoisomer, a mixture of stereoisomers, or a racemic mixture of stereoisomers.

14. The compound according to claim 13 wherein

R 3 is —OR 6 ;

R 5 is aryl (optionally substituted by one or more substituents selected from alkyl, alkoxy, halo, and haloalkoxy);

R 6 is hydrogen, alkyl, aryl, or aralkyl;

R 7a is alkyl;

R 10 is a straight or branched alkylene chain;

R 14 is methyl; and

R 14a is hydrogen.

15. The compound according to claim 14 wherein

R 3 is —OH;

R 5 is optionally-substituted phenyl; and

R 10 is methylene.

16. The compound according to claim 15 wherein

R 5 is 4-fluorophenyl; and

R 7a is methyl or tert-butyl.

17. The compound according to claim 16 , which is

methyl 2-({(4S,5R)-5-[(1E,3E,7E)-(S)-10-(4-fluorophenoxy)-9-hydroxydeca-1,3,7-trien-5-yn-1-yl]-2,2-dimethyl-1,3-dioxolan-4-yl}methoxy)acetate, or

tert-butyl 2-({(4S,5R)-5-[(1E,3E,7E)-(S)-10-(4-fluorophenoxy)-9-hydroxydeca-1,3,7-trien-5-yn-1-yl]-2,2-dimethyl-1,3-dioxolan-4-yl}methoxy)acetate.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2019
From: BAYER INTELLECTUAL PROPERTY GMBH
To: THE BRIGHAM & WOMEN'S HOSPITAL, INC.
Reel/Frame 048753/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2014
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 033292/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2014
From: GROSSBACH, DANJA; GUILFORD, WILLIAM; SANDER, MICHAEL
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 033188/0389 →
CHANGE OF NAME Recorded Jul 1, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 030719/0668 →
CHANGE OF NAME Recorded Nov 11, 2012
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 029277/0286 →
CHANGE OF NAME Recorded Jul 27, 2009
From: SCHERING AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023010/0275 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2006
From: GROSSBACH, DANJA; GUILFORD, WILLIAM; SANDER, MICHAEL
To: SCHERING AKTIENGESELLSCHAFT
Reel/Frame 018626/0876 →